Mid Atlantic Bio Angels

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

Hilltop Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for veterinary applications, particularly for horses and dogs. Established in 2018 and based in Norton, Massachusetts, the company specializes in room temperature placental allograft therapies designed to aid in the regeneration of damaged tissues and reduce inflammation. Hilltop Bio offers a range of products, including ophthalmic membrane patches for eye ulcers, orthopedic injectable treatments for tendon and ligament injuries, and surgical membrane patches that serve as anti-adhesion barriers. The company is committed to delivering safe and effective regenerative therapies that promote rapid healing, addressing key inflammatory diseases in companion and performance animals.

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

DeepLife is a biotech company founded in 2019 and based in Paris, France. The company specializes in developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This innovative approach aims to identify new targets, biomarkers, and potential drug candidates, while also addressing drug resistance and sensitivity. DeepLife operates in a collaborative manner, working alongside academic institutions to ensure a smooth transition from laboratory discoveries to patient applications. The company focuses on leveraging state-of-the-art technologies in systems biology and machine learning to identify molecular triggers that restore cells to their healthy states, thereby accelerating the target identification processes for biotech and pharmaceutical firms.

New View Surgical, Inc. is an innovative medical device company based in Boston, Massachusetts, focused on the development and commercialization of the VisionPort technology. Founded in 2009, the company has created a novel surgical imaging and access system designed specifically for minimally invasive surgery. The VisionPort system consolidates four essential surgical devices—laparoscope, camera, light source, and access port—into a single, user-friendly, disposable device. This integration provides surgeons with enhanced control over both visualization and instrumentation, aiming to address various unmet needs in the market. By simplifying the surgical process, New View Surgical seeks to deliver significant clinical and economic advantages to operating rooms worldwide.

Seneca Therapeutics, Inc. is a biotechnology company dedicated to the development of oncolytic immunotherapeutics for cancer treatment. Its primary product, the Seneca Valley Virus (SVV), is an oncolytic virus engineered to selectively eliminate tumor cells while replicating within them. The company offers SVV in various forms, including cancer therapeutics and vaccines for both cancer and infectious diseases. Founded in 2018 and based in Blue Bell, Pennsylvania, Seneca Therapeutics aims to enhance cancer treatment options by integrating its oncolytic immunotherapeutics with immune checkpoint inhibitors and other cancer vaccines, thereby addressing immune tolerance and providing advanced targeted therapies for a wide range of cancers.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

New View Surgical, Inc. is an innovative medical device company based in Boston, Massachusetts, focused on the development and commercialization of the VisionPort technology. Founded in 2009, the company has created a novel surgical imaging and access system designed specifically for minimally invasive surgery. The VisionPort system consolidates four essential surgical devices—laparoscope, camera, light source, and access port—into a single, user-friendly, disposable device. This integration provides surgeons with enhanced control over both visualization and instrumentation, aiming to address various unmet needs in the market. By simplifying the surgical process, New View Surgical seeks to deliver significant clinical and economic advantages to operating rooms worldwide.

Healionics Corporation is a clinical-stage company based in Seattle, Washington, specializing in the development and manufacture of synthetic biomaterials and implantable medical devices. Founded in 2007, Healionics focuses on addressing critical healthcare challenges, particularly for kidney failure patients requiring dialysis. The company's flagship product, STARgraft, is a synthetic vascular graft designed to provide long-term, reliable blood flow access without the need for frequent interventions, thereby improving patient outcomes and reducing healthcare costs. Additionally, Healionics is developing STARport HD, an implantable device that facilitates needle-free bloodstream access for dialysis, and employs a unique biomaterial technology that enhances the performance of various medical implants by preventing infection and fibrous encapsulation. The company has a robust patent portfolio and established production capabilities, positioning it to enter human clinical studies and market launch in the near future.

Virion Therapeutics, established in 2018 and based in Newark, Delaware, is a biotechnology company focused on developing immune-based treatments for virally-associated cancers and chronic viral infections. The company's primary products are ChiVax and ChiVax-gD vaccines, designed to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These vaccines have demonstrated promising results in pre-clinical testing and are poised for translation into clinical trials targeting diseases such as HPV-induced cancers and chronic Hepatitis B infections.

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

Elysium Therapeutics is a biotechnology company based in Danville, California, established in 2013. The company specializes in developing innovative opioid pain relievers designed to mitigate the risks associated with oral misuse, abuse, and fatal overdose. Elysium Therapeutics' medications incorporate mechanisms that automatically regulate opioid levels in the bloodstream, preventing them from exceeding safe thresholds. This approach not only aims to significantly reduce the potential for addiction and side effects but also provides healthcare practitioners with effective tools for managing pain in patients.

Opsidio is a biotechnology company founded in 2012 and headquartered in Bryn Mawr, Pennsylvania. The company specializes in the development of monoclonal antibodies aimed at treating fibrotic and remodeling diseases. Its innovative approach targets a specific form of the Stem Cell Factor that triggers the release of profibrotic cytokines. This targeted treatment strategy allows for potential therapies for conditions such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, addressing significant unmet medical needs in these areas.

PainQx, Inc. is a healthcare software company founded in 2015 and based in New York, New York. The company specializes in developing innovative solutions for objectively measuring pain in both humans and veterinary applications. Its flagship offering, the PainQx System, utilizes advanced algorithms to analyze neural activity from a patient's brain, producing a scalable biomarker that correlates with the patient's pain state and neurological side effects. This diagnostic tool serves as a clinical assessment method for various organizations, particularly in evaluating the efficacy of drugs and devices where pain is a critical endpoint. PainQx operates on a pay-per-use or subscription model, catering to the needs of medical professionals and researchers aiming for accurate pain assessment, especially in populations that struggle to communicate their pain effectively.

New View Surgical, Inc. is an innovative medical device company based in Boston, Massachusetts, focused on the development and commercialization of the VisionPort technology. Founded in 2009, the company has created a novel surgical imaging and access system designed specifically for minimally invasive surgery. The VisionPort system consolidates four essential surgical devices—laparoscope, camera, light source, and access port—into a single, user-friendly, disposable device. This integration provides surgeons with enhanced control over both visualization and instrumentation, aiming to address various unmet needs in the market. By simplifying the surgical process, New View Surgical seeks to deliver significant clinical and economic advantages to operating rooms worldwide.

Genome Profiling, LLC is a bioinformatics company based in Wayne, Pennsylvania, focused on the discovery of novel epigenetic biomarkers for diagnosing, treating, and predicting chronic and life-threatening diseases. Founded in 2012, the company has developed GenPro Analytics, an innovative software platform that enhances the ability of scientists and medical professionals to predict, diagnose, and monitor disease progression with improved sensitivity, specificity, accuracy, and cost-effectiveness. Genome Profiling offers a unique epigenetic biomarker discovery platform that integrates a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms, allowing for efficient incorporation into standard NGS workflows. This technology enables a single NGS run to yield comprehensive genomic variant call analyses alongside epigenetic data, positioning Genome Profiling at the forefront of the rapidly emerging market in genomic and epigenetic research.

Evrys Bio, LLC is a pharmaceutical company focused on developing innovative antiviral drugs that target sirtuins, proteins that play a crucial role in enhancing the body's intrinsic immune response. The company is engaged in creating broad-spectrum antiviral treatments for various infections, including respiratory syncytial virus, herpes, polyomavirus, and hepatitis viruses. Notably, Evrys Bio aims to offer a pill for treating diverse infections and a brain-penetrant antiviral for conditions like viral encephalitis. By leveraging breakthroughs from Princeton University, Evrys Bio seeks to address the challenge of acquired drug resistance and provide unique treatment options that enhance patient outcomes holistically, rather than targeting specific viruses. Established in 2012 and based in Doylestown, Pennsylvania, the company was formerly known as FORGE Life Science, LLC before rebranding in 2019.

Immunomic Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer, allergies, and animal health. Founded in 2005 and headquartered in Rockville, Maryland, with an additional office in South Korea, the company utilizes its proprietary platforms, including the UNiversal Intracellular Targeted Expression (UNITE) platform and the LAMP-Vax platform. The UNITE platform targets cancer immunotherapy, while LAMP-Vax is designed for DNA vaccines that enhance immune responses by improving antigen presentation. By leveraging lysosomal-associated membrane proteins, Immunomic Therapeutics aims to harness the body’s natural biochemistry to generate robust immune responses, making significant strides in the rapidly evolving fields of allergy and cancer treatment.

Cerus Endovascular Ltd is a medical technology company that specializes in the design and development of interventional neuroradiology devices and delivery systems for the treatment of neurovascular diseases, with a primary focus on intracranial aneurysms. Founded in 2011 and headquartered in Oxford, United Kingdom, with an additional location in Fremont, California, the company has developed the e-clipse device, an innovative aneurysm occlusive solution. This device aims to improve upon existing neurovascular treatment options, including surgical clipping, metal coils, and liquid embolics. Cerus Endovascular's products are specifically designed to assist interventional neuroradiologists in addressing a variety of aneurysm morphologies, including unruptured wide-necked bifurcation and bifurcation aneurysms, thereby enhancing the capabilities for minimally invasive treatment of hemorrhagic strokes and related conditions.